Skip to Content


Main Content

Cancer | 2023

Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.

Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S

PMID: 37021929

Related Articles

CIBMTR Study #: MM20-03

Working Committee: Plasma Cell Disorders